Q2 Solutions, a leading global clinical trial laboratory services organization and subsidiary of IQVIA, announced the expansion of its laboratory and operational capabilities at its Alba Campus in Livingston, Scotland. This expansion of central labs, genomics, flow cytometry, and translational science laboratory services supports growth areas for biopharma and pharma clients around the world.
The expansion includes investments in facilities enhancements and new technologies that will strengthen capabilities and services offered to clients, including:
-
Next-generation genetic sequencing, allowing the identification and analysis of genomic biomarkers that are becoming increasingly important in the understanding of disease and the development of new therapies and drugs.
-
Cutting-edge flow cytometry technologies, allowing the rapid measurement and analysis of cell populations than previously available to support clinical trials globally. This enables Q2 Solutions to greatly enhance its capability to provide useful, unique, and highly complex data to clients.
-
Creation of a dedicated clean room for peripheral blood mononuclear cell (PBMC) isolation, used in a wide range of research and clinical areas such as HIV research and cancer immunotherapy.
“Expanding our capabilities at the Alba Campus reaffirms our commitment, within an ever-changing global regulatory landscape, to providing integrated laboratory services to regional and global biopharmaceutical companies,” said Tony Brown, Q2 Solutions, Vice President and General Manager, Global Central Laboratories. “Our expanded Scottish facility reinforces our position as one of the leading clinical trial laboratories in Europe.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!